Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Advanced Therapies Integrates North 2025

Advanced Therapies Integrates North 2025 brings together industry leaders to unlock the full potential of Advanced Therapies and Medicinal Products (ATMPs). The event spotlights key [...]

Go to Top